Research projects

  • Therapeutic drug monitoring of biologic drugs, including TNF inhibitors and other therapeutic antibodies.
  • Personalised treatment in multiple sclerosis, including measurement of rituximab and natalizumab drug levels and anti-drug antibodies (PhD project).
  • Personalised treatment by serum level and anti-drug antibody measurements of biologic drugs in early rheumatoid arthritis (PhD project).
  • Development of assays for measuring CGRP inhibitors fremanezumab, galcanezumab and erenumab used in preventive migraine treatment (planned PhD project).
  • Introduction of checkpoint inhibitors to routine diagnostics and development of relevant assays for anti-drug antibodies.
  • Therapeutic drug monitoring of biologic drugs in children with juvenile idiopathic arthritis.
  • Detection of antibodies to transglutaminase in the HUNT4 cohort using an in-house dual label assay in the collaborative study “Coeliac disease in HUNT”.
  • Liquid biopsy: Development of new tumour markers detecting cancer DNA in plasma (circulating tumour DNA) using droplet digital PCR (ddPCR), for example KRAS and HPV markers.
  • Interference in immunoassays, including heterophilic antibodies and macrocomplexes, with diagnostic support available upon request.
  • Development of custom coated microplates for improved immunoassay performance. Custom coated microplates are available upon request.

Clinical studies and collaborations

RA-DRUM is a randomised clinical trial investigating whether therapeutic drug monitoring (TDM) of tumour necrosis factor inhibitors improves treatment outcomes in rheumatoid arthritis. The study evaluates whether dose adjustment based on serum drug concentrations and anti-drug antibody measurements leads to better efficacy. RA-DRUM is part of the SQUEEZE project, a large European collaboration funded by Horizon Europe focusing on optimised use of existing therapies in rheumatoid arthritis. The study is led by REMEDY, Diakonhjemmet Hospital.

 
Scroll to top